FDA Signs Off on Adaptimmune’s Tecelra

Patients with a certain type of synovial sarcoma have a new treatment option for the first time in more than a decade as the FDA has approved Adaptimmune’s Tecelra, which is the first engineered T-cell therapy for a solid tumor.